© 2020 MJH Life Sciences and OncLive. All rights reserved.
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
October 23rd 2020
Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.
Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.
Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.
Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.
Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.
Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.
Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.
Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.